Added: Dec 3, 2008
From: MultiVuOnline
Duration: 3:44
Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and PainResults from Phase 3b Studies with Durezol Dosed Prior to SurgerySirion Therapeutics, Inc., a privately held ophthalmic-focused biopharmaceutical company, announced today that Durezol™ (difluprednate ophthalmic emulsion) 0.05% is now commercially available. Durezol, which was approved by the U.S. Food and Drug Administration in June 2008, is a topical ophthalmic corticosteroid indicated for the treatment of inflammation and pain associated with ocular surgery.To view Multimedia News Release, go to http://www.prnewswire.com/mnr/durezol/34934/
Channel: News
Tags: 35319 corticosteroid durezol inflammation multivu ocular ophthalmic pain postoperative sirion
Rating: ( ratings) Views: 49 Comments: 0